163 related articles for article (PubMed ID: 34818480)
1. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
Kamihara J; Hamilton KV; Pollard JA; Clinton CM; Madden JA; Lin J; Imamovic A; Wall CB; Wassner AJ; Weil BR; Heeney MM; Vargas SO; Kaelin WG; Janeway KA; Perini RF; Zojwalla NJ; Voss SD; DuBois SG
N Engl J Med; 2021 Nov; 385(22):2059-2065. PubMed ID: 34818480
[TBL] [Abstract][Full Text] [Related]
2. Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient.
Abdallah A; Pappo A; Reiss U; Shulkin BL; Zhuang Z; Pacak K; Bahrami A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28096. PubMed ID: 31876082
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male.
Toyoda H; Hirayama J; Sugimoto Y; Uchida K; Ohishi K; Hirayama M; Komada Y
Pediatrics; 2014 Jun; 133(6):e1787-91. PubMed ID: 24819565
[TBL] [Abstract][Full Text] [Related]
4. A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options.
Jochmanova I; Lazurova I
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):175-80. PubMed ID: 24781045
[TBL] [Abstract][Full Text] [Related]
5. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
[TBL] [Abstract][Full Text] [Related]
6. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.
Pang Y; Gupta G; Jha A; Yue X; Wang H; Huynh TT; Li A; Li L; Baker E; Chew E; Feelders RA; Korpershoek E; Zhuang Z; Yang C; Pacak K
Cancer; 2019 Apr; 125(8):1258-1266. PubMed ID: 30644531
[TBL] [Abstract][Full Text] [Related]
7. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
Buffet A; Smati S; Mansuy L; Ménara M; Lebras M; Heymann MF; Simian C; Favier J; Murat A; Cariou B; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2014 Feb; 99(2):E369-73. PubMed ID: 24276449
[TBL] [Abstract][Full Text] [Related]
8. Pacak-Zhuang syndrome: a model providing new insights into tumor syndromes.
Rosenblum JS; Wang H; Nazari MA; Zhuang Z; Pacak K
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37450881
[TBL] [Abstract][Full Text] [Related]
9. Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome.
Dmitriev PM; Wang H; Rosenblum JS; Prodanov T; Cui J; Pappo AS; Gilbert MR; Lutty GA; Chan CC; Chew EY; Pacak K; Zhuang Z
JAMA Ophthalmol; 2020 Feb; 138(2):148-155. PubMed ID: 31876943
[TBL] [Abstract][Full Text] [Related]
10. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.
Zhuang Z; Yang C; Lorenzo F; Merino M; Fojo T; Kebebew E; Popovic V; Stratakis CA; Prchal JT; Pacak K
N Engl J Med; 2012 Sep; 367(10):922-30. PubMed ID: 22931260
[TBL] [Abstract][Full Text] [Related]
11. Chiari Malformation Type 1 in
Rosenblum JS; Maggio D; Pang Y; Nazari MA; Gonzales MK; Lechan RM; Smirniotopoulos JG; Zhuang Z; Pacak K; Heiss JD
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185588
[TBL] [Abstract][Full Text] [Related]
12.
Nagano Y; Inoue M; Uchida K; Otake K; Kusunoki M
Pediatr Int; 2020 Feb; 62(2):231-232. PubMed ID: 32104990
[No Abstract] [Full Text] [Related]
13. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.
Taïeb D; Yang C; Delenne B; Zhuang Z; Barlier A; Sebag F; Pacak K
J Clin Endocrinol Metab; 2013 May; 98(5):E908-13. PubMed ID: 23539726
[TBL] [Abstract][Full Text] [Related]
14. Belzutifan: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
[TBL] [Abstract][Full Text] [Related]
15. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
16. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
[TBL] [Abstract][Full Text] [Related]
17. Deficiency in PHD2-mediated hydroxylation of HIF2α underlies Pacak-Zhuang syndrome.
Ferens FG; Taber CC; Stuart S; Hubert M; Tarade D; Lee JE; Ohh M
Commun Biol; 2024 Feb; 7(1):240. PubMed ID: 38418569
[TBL] [Abstract][Full Text] [Related]
18. HIF2A mutations in paraganglioma with polycythemia.
Favier J; Buffet A; Gimenez-Roqueplo AP
N Engl J Med; 2012 Nov; 367(22):2161; author reply 2161-2. PubMed ID: 23190243
[No Abstract] [Full Text] [Related]
19. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
